ReviewCell & bioscience2025
Old dogs-new tricks: multifaceted functions of MAVS beyond antivirus activity in human health and diseases.
Review in Cell & bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Mitophagy in neuronal health and disease: from mechanisms to neurodegeneration.The Journal of clinical investigation · 2026Review
- Cyclo-C stabilizes PEX13 to inhibit porcine epidemic diarrhea virus replication by blocking pexophagy-mediated disruption of antiviral innate immunity.Journal of virology · 2026Article
- Metabolic-Epigenetic Crosstalk in Takayasu Arteritis: The ANK2-MAVS-IL-8 Axis as a Novel Therapeutic Paradigm.International journal of molecular sciences · 2026Review
- Article
- Crosstalk between innate immune signaling pathways and integrated TLR, NLRP3 inflammasome, cGAS-STING, and NF-κB networks in sepsis.Frontiers in cell and developmental biology · 2026Review
- Aspergillus fumigatus Gliotoxin Inhibits LC3-Associated Phagocytosis in Macrophages in a Calcium-Dependent Manner.Journal of immunology research · 2026Article
- Intelligent design of tumor microenvironment-responsive Adeno-associated virus vectors: overcoming delivery barriers and enabling precision therapy.Medical oncology (Northwood, London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Mitochondrial Antiviral Signaling Protein (MAVS), a key adaptor in the innate immune system, has traditionally been recognized for its role in defending against viral infections through activation of the interferon (IFN) and NF-κB signaling pathways. Recent studies, however, have expanded this view, revealing that MAVS also functions at the intersection of innate immunity, mitochondrial dynamics, and cellular metabolism. Located on the outer mitochondrial membrane, MAVS serves as a critical signaling hub, linking pathogen detection to inflammatory and stress responses. Beyond its canonical antiviral roles, MAVS is now implicated in diverse physiological and pathological processes, including regulation of apoptosis, NLRP3 inflammasome activation, metabolic reprogramming, and autophagy. Its dysregulation contributes to the onset and progression of a range of diseases, such as cancer, cardiovascular and autoimmune disorders, and neurological conditions. This review provides a comprehensive overview of MAVS activation, downstream signaling outputs, and regulatory mechanisms. We also discuss the emerging evidence on MAVS-related diseases and therapeutic strategies targeting MAVS, emphasizing its broader significance in human health beyond antiviral immunity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.